Last reviewed · How we verify
Hyperbaric Bupivacaine HCl 0.5% 10 mg
At a glance
| Generic name | Hyperbaric Bupivacaine HCl 0.5% 10 mg |
|---|---|
| Also known as | 20% reduced dose of hyperbaric bupivacaine |
| Sponsor | Aswan University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Doses of Intrathecal Dexmedetomidine (PHASE4)
- Intrathecal MoRphine Versus Transabdominal Plane Block (TAP) Block for AnalGesic Management in Elective Caesarean Section (PHASE4)
- Effect of Patient Position on Bupivacaine Dose Requirement and Hemodynamic Stability in Spinal Anesthesia (NA)
- Intrathecal Dexamethasone and Atropine on Morphine Induced Post-operative Nausea and Vomiting on Caesarean Section (NA)
- Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine (PHASE4)
- Comparative Dose-Response of Intrathecal Dexmedetomidine for Post-Spinal Shivering (PHASE3)
- Machine Learning for Predicting Spinal Anesthesia Duration
- Effect of Dexmedetomidine on the Quality of Recovery in Parturients Undergoing Elective Caesarean Sections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperbaric Bupivacaine HCl 0.5% 10 mg CI brief — competitive landscape report
- Hyperbaric Bupivacaine HCl 0.5% 10 mg updates RSS · CI watch RSS
- Aswan University portfolio CI